Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Bar

Tom Brody;

Publication

Article

February 15, 2002

BioPharm International

BioPharm International-02-01-2002

Volume15

Issue 2

Pages: 38-42

Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Bar

Author(s):

Tom Brody

By Tom Brody, DNAX Research Institute, pp. 38-42. Early sale or offers to sell an invention may result in the rejection of a patent application under 35 U.S.C. 102(b). Such a rejection is called "the on-sale bar," and it permanently prevents patenting of an invention.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Using a Model and Tools to Standardize the Preparation for a Preapproval Inspection

Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Bar

Outsourcing Outlook: Reaping the Benefits of E-Procurement

The Immunogenicity of Therapeutic Proteins

Analytical Advances: Calibration Management of Outsourced Calibrations

High-Throughput Biopharmaceutical Drug Development: Meeting the Coming Challenge

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Bar

Newsletter